When I started work, if you wanted to tell someone something, you wrote a handwritten note, posted it internally to a typing pool, told them how many copies you wanted, and a few days later things would turn up in the internal post. To distribute things further, you had to then fill envelopes, lick stamps and then post them. (For the youth reading this, Google any of the unfamiliar words/phrases). It was incredible that anything got done at all (penicillin, the transistor, gps, etc it really is.
We live in different times, and as a group we communicate in three general ways to the world.
The ChEMBL-og chembl.blogspot.com - this blog! Mostly news of broad interest, some ephemera, some recruitment, and some analyses of data, new drug approval news, interesting papers, conferences, book and hotel reviews for scientists, etc. The Group homepage at www.ebi.ac.uk/chembl - links to the online resources (currently kinase sarfari and chembldb are live). The ChEMBL twitter feed www.twitter.com/ch…
We have a new position available within the ChEMBL group from January 2010 onwards - the role is for someone to do data integration, analysis, and work-flow prototyping for chemogenomics/bioassay data. The post should be advertised on the EMBL recruitment website soon, there are also several other excellent jobs listed at EMBL-EBI.
The deadline for application for bursaries for the small molecule bioactivity course at the EMBL-EBI is approaching - Friday November 6th. If you wish to attend for free (or at a really discounted rate) please consider applying now. We are starting to assemble the material for the course now, and have secured some truly outstanding external speakers - it should be good!
There is, what looks like, an excellent meeting in London, full details are on the SMR website. I hope I feel better by then.
SMR Award Meeting: Recent Disclosures of Clinical Candidates 10th December 2009 National Heart & Lung Institute, Kensington, London Programme:
09.30 Registration and coffee 10.00 SMR Award lecture: The Discovery and development of Januvia™,Dr. Ann Weber, Merck
(Introduction by - Rob Williams, Cancer Research UK) Session 1 - Chair: Mark Searcy, University of East Anglia 11.00 Chris Murray, Astex From fragment to clinic - the discovery of the hsp90 inhibitor, AT13387. 11.45 George Muller, Celgene The discovery of apremilast. 12.30 Lunch (Including SMR AGM 13.10-13.30) Session 2 - Chair: Diane Coe, GSK 13.30 David Fox, Pfizer The discovery of a second generation long-acting PDE5 inhibitor. 14.15 Simon Hodgson, GSK The discovery of a dual H1/H3 antagonist for allergic rhinitis. 15.00 Tea Session 3 - Chair: David Fox, Pfizer 15.30 Karl Gibson, Pfizer The discovery of a progesterone recept…
So, we have an initial interface for the ChEMBL SAR data, and we are looking for some interested people to do some testing, find issues with different OS, browsers, java versions, etc. The kinase SARfari testing we did was very helpful, and many, many thanks to those of you that helped, but rest assured, we will mail you for feedback, bugs, etc.
If you wish to take part, please mail us
We have released an update to Kinase Sarfari, the major changes are:
Frontend ChangesCompound report card now displays smiles, inchi, inchi_key
Bioactivity data download now includes smiles
User guide updated
Starlite references changed to ChEMBL
Backend ChangesMigrated kinasesarfari schema from chemdev to chempro (an internal trifle, but important to us ;)
Schema clean up
Thanks for all the feedback!
Also approved on September 25th was Pralatrexate (tradename Folotyn). Pralatrexate is the first drug approved for the treatment of Peripheral T-Cell Lymphoma (PTCL), an aggressive form of non-Hodgkins lymphoma. Lymphoma is a cancer that begins in the lymphocytes of the immune system. PTCL is a rare disease, occurring in around 9,500 patients each year in the United States.
Pralatrexate, also known as PDX, is a folic analog that competitively inhibits dihydrofolate reductase (DHFR). Since Pralatrexate blocks the use/function of a metabolite, it is also an antimetabolite. Pralatraxate has high affinity for the folate transporter SLC19A1 (also known as RFC-1), and so is an example of a drug that is 'actively transported', and is also a substrate for polyglutamation by the enzyme folylpolyglutamate synthase (FPGS). Once polyglutamated Pralatrexate has a prolonged intracellular half-life, giving prolonged action in malignant cells. Pralatrexate is related to several other drugs, …